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Abstract There is increasing interest in methods to
disentangle the relationship between genotype and
(endo)phenotypes in human complex traits. We present a
population-based method of increasing the power and cost-
efficiency of studies by selecting random individuals with a
particular genotype and then assessing the accompanying
quantitative phenotypes. Using statistical derivations,
power- and cost graphs we show that such a ‘‘forward
genetics’’ approach can lead to a marked reduction in
sample size and costs. This approach is particularly apt for
implementing in epidemiological studies for which DNA is
already available but the phenotyping costs are high.
Keywords Power  Forward genetics  Complex traits 
Selective sampling  Phenomics
Introduction
Several genome-wide association studies have recently
identified novel susceptibility loci for medical conditions
such as diabetes mellitus and schizophrenia (Barret et al.
2009; Stefansson et al. 2009). This has increased the need
to investigate the phenotypic differences that are conferred
by such quantitative trait loci. However, due to the small to
modest contributions of single loci to most complex traits,
such phenotypic differences are hard to detect. The prob-
lem of small effect sizes of specific alleles or haplotypes is
compounded by the complexity of many of the traits of
interest. Most candidate genes have been identified in
subjects with a disorder that incorporates a broad variety of
symptoms. The co-occurrence of several symptoms at once
can be the result of pleiotropic effects of a singe variant,
but may also be due to the underlying abnormality. Many
disorders coincide with physical, emotional, and social
abnormalities; for example, depression is associated with
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cognitive problems, cardiovascular risks and social prob-
lems, among others. These concomitant phenomena are
likely to influence the expression of the original trait, and
may well obscure the initial relationship between a can-
didate gene and a trait. As a consequence, the particular
symptoms or abnormalities associated with these genes
remain unclear.
We, therefore, propose reversing the process: instead of
selecting a trait and examining its relationship with the
underlying genes, we will select genetic variation and
examine the accompanying trait. Testing the influence of a
particular gene on phenotypes is a common approach in
both animal and molecular research, where the influence of
genetic variation is often studied by inbreeding the genetic
variant by creating a knockout mouse, or by transposing the
variant of interest into cell cultures or organisms by means
of a vector. The statistical power of an association test for a
candidate gene depends on the distribution of genotypes in
the test population. A maximum statistical power for a
given number of phenotyped individuals is obtained when
the test population consists of equal numbers of alternative
homozygotes at the candidate gene (as is the case when the
two alleles at the candidate gene are of equal frequency).
However, since allele frequencies at the candidate gene
locus are generally far from equal, the distribution of
informative alleles in the population as a whole is generally
far from this optimal distribution. Thus, depending on the
relative costs of determining phenotypes compared to the
cost of genotypes, it may be more effective to genotype a
large sample population and then choose a set of individ-
uals with an optimal distribution of genotypes for further
phenotyping. Here we provide information on the statistical
power under different genotype sampling strategies, as a
function of explained variance, dominance and allele fre-
quency at the candidate gene, and on phenotype/genotype
cost ratios.
Selecting subjects from the general population based on
homozygosity for a candidate gene instead of subjects with
an apparent disorder has two major advantages. (1) It
means the investigation of the relationship with genotype is
unbiased by selection for severity of disease, and we
therefore avoid bias as a result of secondary symptoms. (2)
This approach facilitates the estimation of the effects of
single variants in relative isolation, because the selection is
not based on phenotype. As a consequence, there is no
selection for the presence of additional risk variants for that
particular phenotype although it will shift the distribution
of the phenotype.
The value of such a ‘‘forward genetics’’ approach is seen
in the increase in statistical power and its cost-effective-
ness. As already pointed out, the increase in power is due to
the selection of the most informative subjects. Other
strategies, such as the extreme discordant and concordant
design (Risch and Zhang 1995), in essence do the same by
selecting extreme phenotypes. With the ever reducing costs
of genotyping, our strategy only has merit if the cost of
obtaining phenotype information is high. In studies of
complex and quantitative phenotypes, such as those that
apply costly neuroimaging, this approach can be particu-
larly advantageous.
We investigated the sample size requirement of this
approach and the cost-effectiveness under different
scenarios.
Methods
The sample size requirements depend on the proportion of
variance explained by the genetic effect, allele frequencies,
and the genetic model (Falconer and Mackay 1996). In our
description of the genetic model, we follow Falconer’s
notation, in which the mean genotypic values of the A1A1,
the A1A2, and A2A2 genotypes are denoted as ?a, d, and
-a, respectively. The total variance of a phenotype (VP)
can be broken down into the variance due to one particular
locus (VG), and the remaining genotypic and environ-
mental variance VR. VG can be further divided into the
additive genetic (VA) and the dominant genetic variance
components (VD), such that:
VG ¼VA þ VD ¼ 2pq[a þ d(q  p)2 þ ½2pqd]2 ; ð1Þ
where p and q denote the allele frequencies of the wildtype
and risk alleles, respectively. Rearranging formula (1)




2pq 1 þ d=a q  pð Þð Þ2þ 2pqð Þ2 d=að Þ2
 h i0:5
ð2Þ
Based on the chosen values of p, q, d/a, VG, the total
number of selected individuals (N), and the selected
number of individuals from each genotype group, we can
derive the statistical power from a calculation of the F
statistic. In order to calculate the F statistic, we first
calculated the total mean, the within-group means, the
within-group sum of squares (sswithin) and the between-
group sum of squares (ssbetween). The within-group means
of the three genotype groups do not change as a result of
selection and are therefore equal to ?a, d, and -a, for the
A1A1, the A1A2, and A2A2 genotypes. Denoting pr[A1A1],
pr[A1A2], and pr[A2A2] as the proportions of the three
genotype groups after selection, the total mean, ssbetween,
and sswithin were calculated as
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Total mean ¼ Meant ¼ pr A1A1½   a þ pr A1A2½   d
 pr A2A2½   a
sswithin ¼ VR  N
ssbetween ¼ pr A1A1½   N  a  meantð Þ
þ pr A1A2½   N  d  meantð Þ
þ pr A2A2½   N  meant  að Þ ð3Þ
The F statistic is defined as
F ¼ ssbetween= k  1ð Þ½ = sswithin= N  kð Þ½ ð4Þ
with k denoting the number of groups, i.e., k = 3 (homo-
zygotes and heterozygotes) or 2 (homozygotes only).
Finally, we calculated the non-centrality parameter
(NCP), i.e., F*(N - k), and the statistical power based on
this parameter and a chosen alpha. We compared the NCP
calculated with that provided by the genetic power calcu-
lator (Purcell et al. 2003). The application can be extended
for scenarios where more genes are considered (see sup-
plementary R script). We performed illustrative power and
costs analyses under several scenarios, including one in
which we selected three genes and subjects were available
that were homozygous for two of the rare homozygous
variants and heterozygous for the third variant compared to
subjects that were homozygous for all three common
variants. The calculations were carried out in R (R
Development Core Team 2005).
Results
Figure 1 shows the power with a type I error rate of 0.05
for different sampling strategies in a fully additive model,
with an explained variance of genotype of 0.03 and a risk
allele frequency of 0.3. This effect size is within the range
of effect sizes reported by recent genome-wide association
studies. As can be seen in Fig. 1, 100 homozygous subjects
were sufficient to provide a power of 0.80 for detecting
phenotypic differences at a significance level of 0.05. This
constitutes a more than fourfold reduction in the sample
size required compared to a strategy with random selection.
Figure 2 shows the superior power of a sample strategy in
which participants were selected for three loci. Illustrative
power graphs obtained under different scenarios (explained
variances, dominance and allele frequencies) are presented
in Figs. 3, 4 and 5. Figure 3 shows that the power is
favorable regardless of the amount of explained variance of
the genetic variant, but the gain is higher in scenarios
where the genetic variant explains only a limited propor-
tion of the phenotypical differences. Figure 4 shows that
the gain is highest in scenarios with a fully additive genetic
model, while Fig. 5 shows that the gain is highest in sce-
narios where the allele frequency of the genetic variant is
low. This is logical, considering that the impact of selecting
for genotype is highest in these situations. The cost-
effectiveness is depicted in Figs. 6 and 7 for different ratios
of phenotyping and genotyping costs. In the case where the
phenotyping cost is $10 and genotyping is $1, the ratio is
10. In scenarios where the phenotyping information is
already available, the ratio is zero. We here depicted ratios
of 0, 200, 700, and 1,000. At present, genome-wide
genotyping is less than $0.001 per genotype and costsFig. 1 Power achieved under different sampling strategies
Fig. 2 Power for a sampling strategy where three genes were
selected and subjects were available that were homozygous for two of
the rare homozygous variants and heterozygous for the third variant
compared to subjects that were homozygous for all three common
variants
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Fig. 3 The power of sampling strategies under different assumptions of explained variance
Fig. 4 The power of sample strategies under different assumptions of dominance
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about $300–$700 per subject, depending on the platform
and reagents; e.g., Taqman for single SNPs costs roughly
$0.20–1. Generally, the true cost of phenotyping is mani-
fold more and should include staff salaries for (clinical)
assessments, laboratory work and material expenses. In
cases where MRI or PET imaging is involved, phenotype/
genotype cost ratios may easily exceed 1,000. Figures 6
and 7 show that the cost reduction is highest in those
scenarios in which the allele frequency of the genetic
variant is low and increases as the phenotyping costs
increase. The cost reduction decreases as the variance
explained by the genotype increases (Fig. 7).
Discussion
We have demonstrated that ‘‘forward genetics’’ is a cost-
effective method for investigating genotype–phenotype
associations in complex human traits. The figures, formulas
and R-script provided can be used to estimate the sample
size required under different conditions and our calcula-
tions show that a marked increase in power and reduction
of costs can be obtained by this approach, particularly for
those scenarios with relatively high phenotyping costs.
Considering the ever reducing costs of genotyping, and the
use of increasingly complex phenotypes, such as measures
of brain volume obtained with MRI, these scenarios are
frequently encountered. If, for instance, after pooling of
data on hippocampal volume in a consortium (covering
several hundreds of subjects), genome-wide analysis yields
a few, significantly associated loci, it would make sense to
type these loci in a large population sample and to obtain
MRI scans in two groups based on the selection of all these
SNPs in order to maximize power. Clearly, such a repli-
cation sample could also be used for further genome-wide
analysis, but at least the sample would be optimal for
replicating the effects found. This method, therefore, is a
Fig. 5 The power of sample strategies under different assumptions of allele frequencies
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Fig. 6 The costs as a function of phenotype/genotype cost ratio under different allele frequencies
Fig. 7 The costs as a function of explained variance by the sequence variant under different phenotype/genotype costs ratios
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cost-effective way to confirm previously reported genetic
association signals, to refine genotype–phenotype rela-
tionships, and thus to facilitate the discovery of suscepti-
bility loci in complex quantitative traits. Extensions of this
design, in which subjects are selected on the basis of two or
more genetic variants, have been presented here. Interac-
tion between the genes can subsequently be tested as a
measure of epistasis.
Applying forward genetics can be particularly helpful
in studies where DNA is available as part of an epide-
miological (longitudinal) study. We plan to use this
approach for the study of cognitive and brain volumetric
phenotypes in a large, population-based epidemiological
sample from the Netherlands. This study will be per-
formed as part of the Utrecht Health Project (Grobbee
et al. 2005). In this design DNA of more than 6,000
subjects is available for genotyping. Subjects homozygous
for alleles that are associated with cognitive traits, and
subjects homozygous for the wildtype allele, will be
invited for further comprehensive assessments. Our power
analyses show that a number of N = 90 per genetic
variant will be sufficient to obtain a type I error rate of
0.007 and a power of 0.8. We plan to comprehensively
assess the psychological-, cognitive-, and social func-
tioning of the selected subjects in order to test seven
different phenotypes. The raters and participants will
remain blind to the subject’s genotype status in order to
avoid phenotyping bias and ethical complications. The
classical approach would be to assess a large numbers of
participants from the epidemiological study and to per-
form a case–control association analysis or quantitative
trait locus (QTL) analysis. As pointed out above, the costs
of assessing the large numbers of participants required in
the conventional design would be much higher compared
to the forward genetics approach. Particularly in cases
where the genetic variant is rare and many assessments
would be required to obtain sufficient power.
Our approach differs from the recently advocated
‘‘reverse phenotyping’’ approach (Schulze and McMahon
2004), in which both genotype and phenotype information is
assumed to be available. The phenotype–genotype rela-
tionship is, however, re-assessed by revisiting phenotypes
(reverse phenotyping). Clearly, a strong argument for
Schulze and McMahon’s approach (Schulze and McMahon
2004) can be made and there are several recent studies that
have successfully applied such reverse phenotyping (Tilley
et al. 1998; Silverman et al. 2002; Schaid et al. 2006).
However reverse phenotyping cannot solve the power issue,
which is relevant to the investigation of rarer genetic vari-
ants; nor does it result in a cost reduction in the study of
expensive phenotypes, such as those based on brain imaging.
Overall, our analyses demonstrate that forward genetics can
be a useful tool for studying more complex and expensive
behavioral phenotypes in the context of epidemiological
studies.
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